Stocks
Amylyx Pharmaceuticals (AMLX) Debt/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | -0.88 | 0.30 | 1.16 | 1.69 | -9.20 | 4.62 | |||
| Changes by years, y/y, % | -133% | +293% | +46% | -644% | +79.6% | ||||
Amylyx Pharmaceuticals. Debt/EBITDA
Amylyx Pharmaceuticals. Debt/EBITDA, changes, %
Amylyx Pharmaceuticals (AMLX) Debt/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| Debt/EBITDA | 2.19 | 4.36 | 49.0 | -9.25 | 4.62 | 4.62 | ||
| Changes by years, y/y, % | +20% | +315% | +7 590% | -646% | +111% | |||
| Changes by quarters, q/q, % | +29% | +99% | +1 024% | -119% | -150% | |||
